[4-(2,6-dimethylmorpholin-4-yl)phenyl]methylamine | 581812-67-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: [4-(2,6-dimethylmorpholin-4-yl)phenyl]methylamine
• 英文别名: (4-(2,6-Dimethylmorpholino)phenyl)methanamine；[4-(2,6-dimethylmorpholin-4-yl)phenyl]methanamine
• CAS: 581812-67-1
• 化学式: C₁₃H₂₀N₂O
• mdl: MFCD11135260
• 分子量: 220.315
• InChiKey: WYSREDZTTQWKFG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.538
• 拓扑面积：
  38.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  [4-(2,6-dimethylmorpholin-4-yl)phenyl]methylamine 、 5-异氰酸异喹啉 在 methanol-dichloromethane 作用下， 生成 N-[4-(2,6-dimethyl-4-morpholinyl)benzyl]-N'-5-isoquinolinylurea
  参考文献：
  名称：

  Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1(VR1) receptor

  摘要：

  式(I)的化合物是新型的VR1拮抗剂，可用于治疗疼痛、炎症性热性过敏、尿失禁和膀胱过度活动，其中X1、X2、X3、X4、X5、R5、R6、R7、R8a、R8b、R9、Z1、Z2和L在描述中有定义。

  公开号：

  US07335678B2
• 作为产物：
  描述：

  4-(2,6-dimethylmorpholino)benzonitrile 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 生成 [4-(2,6-dimethylmorpholin-4-yl)phenyl]methylamine
  参考文献：
  名称：

  In Vitro Structure−Activity Relationship and In Vivo Characterization of 1-(Aryl)-3-(4-(amino)benzyl)urea Transient Receptor Potential Vanilloid 1 Antagonists

  摘要：

  The synthesis and structure-activity relationship of 1-(aryl)-3-(4-(amino)benzyl)urea transient receptor potential vanilloid 1 (TRPV1) antagonists are described. A variety of cyclic amine substituents are well tolerated at the 4-position of the benzyl group on compounds containing either an isoquinoline or indazole heterocyclic core. These compounds are potent antagonists of capsaicin activation of the TRPV1 receptor in vitro. Analogues, such as compound 45, have been identified that have good in vivo activity in animal models of pain. Further optimization of 45 resulted in compound 58 with substantially improved microsome stability and oral bioavailability, as well as in vivo activity.

  DOI：

  10.1021/jm070276i

文献信息

• Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
  申请人：——

  公开号：US20040157849A1

  公开（公告）日：2004-08-12

  Compounds of formula (I) 1 are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.

  式（I）的化合物是新颖的VR1拮抗剂，可用于治疗疼痛、炎症性热性过敏、尿失禁和膀胱过度活动。
• [EN] THERAPEUTIC MACROLIDE COMPOUNDS AND THEIR USE<br/>[FR] COMPOSÉS DE MACROLIDES THÉRAPEUTIQUES ET UTILISATION DE CEUX-CI
  申请人：MERLION PHARMACEUTICALS PTE LT

  公开号：WO2010062265A1

  公开（公告）日：2010-06-03

  The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain macrolide compounds (for convenience, collectively referred to herein as "MC compounds"), which, inter alia, are useful in treatment of cancer. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to treat proliferative conditions such as cancer, and in the treatment of diseases and conditions that are mediated by the regulation (e.g. inhibition) of cell proliferation, optionally in combination with another agent.

  本发明一般涉及治疗化合物领域，更具体地涉及某些大环内酯化合物（为方便起见，本文统称为“MC化合物”），这些化合物在癌症治疗中有用。本发明还涉及包含这些化合物的药物组合物，以及利用这些化合物和组合物在体外和体内治疗增殖性疾病，如癌症，并在治疗通过细胞增殖调控（例如抑制）介导的疾病和病症方面的用途，可选地与另一药剂结合。
• [EN] FUSED AZABICYCLIC COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR<br/>[FR] COMPOSES AZABICYCLIQUES FUSIONNES QUI INHIBENT LE RECEPTEUR (VR1) SOUS-TYPE 1 DU RECEPTEUR VANILLOIDE
  申请人：ABBOTT LAB

  公开号：WO2003070247A1

  公开（公告）日：2003-08-28

  Compounds of formula (I), are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.

  化学式为(I)的化合物是新颖的VR1拮抗剂，可用于治疗疼痛、炎症性热性过敏、尿失禁和膀胱过度活动。
• Fused azabicycic compounds that inhibit vanilloid receptor subtype 1(VR1) receptor
  申请人：——

  公开号：US20040209884A1

  公开（公告）日：2004-10-21

  Compounds of formula (I) 1 are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.

  式(I)1的化合物是一种新型的VR1拮抗剂，可用于治疗疼痛、炎性热性过敏、尿失禁和膀胱过度活动。
• FUSED AZABICYCLIC COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR
  申请人：LEE CHIH-HUNG

  公开号：US20080214524A1

  公开（公告）日：2008-09-04

  Compounds of formula (I) are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.

  公式（I）的化合物是新型的VR1拮抗剂，可用于治疗疼痛、炎症性热痛敏、尿失禁和膀胱过度活动。